Why Bausch Health Companies Inc. (TSX:BHC) Is a Genius Bet for Long-Term Growth Investors

Bausch Health Companies Inc. (TSX:BHC)(NYSE:BHC) is a must-own stock for rebound hunters. Here’s why.

| More on:

Bausch Health Companies (TSX:BHC)(NYSE:BHC), formerly known as Valeant Pharmaceuticals, has moved on from its troubled past. New CEO Joseph Papa has done an applaud-worthy job of turning the sinking ship that was Valeant into a firm that’s not only capable of surviving, but one that’s poised for a strong return to the growth track. But this time around, it’s all about organic growth, not debt-fueled acquisitive growth with little to no consideration for R&D or solvency.

Simply put, Bausch is an entirely different company than Valeant was before its collapse. It’s a legitimate pharma player with excellent stewardship, terrific assets, and an ambitious turnaround plan.

Most recently, Bausch reached a settlement with generic drug firm Teva Pharmaceuticals that will delay Xifaxan’s generic launch to January 2028. This delay is a big deal for Bausch, as the gastro-focused drug is a crucial pillar of Bausch’s cash flow stream with approximately $1.2 billion in revenues (14% of overall revenues) expected for 2018 to go with robust year-over-year growth moving forward.

David Steinberg, an analyst at Jefferies, believes that the risk of bankruptcy is “off the table” following the settlement. While such commentary from a well-respected analyst is promising, there’s still a considerable amount of debt on the balance sheet that’s still less than ideal, so the company is by no means out of the woods just yet.

The Teva settlement will allow Bausch’s management team more flexibility when it comes to investment in organic growth initiatives, however. A lesser degree of uncertainty with regards to the long-term outlook for Xifaxan’s cash flow stream will allow management to pull different levers to better meet longer-term debt obligations such that the probability of further asset divestments will be lowered substantially.

Foolish takeaway

Sure, Bausch remains highly leveraged, and there’s still a considerable amount of uncertainty with regards to the future success of drugs in the pipeline, but one has to give credit where credit is due. Mr. Papa is a smooth operator, and he’s turned the uninvestable “sinking ship” of a company into one that could realistically surprise and silence all the doubters.

While overall financial wiggle room may be limited compared to the likes of a peer south of the border, I think Mr. Papa’s expertise is well worth the price of admission. He’s a seasoned veteran when it comes to the world of pharma. He knows the ins and outs of the over-the-counter drug business, and I think it’s just a matter of time before he and his team iron out all Bausch’s ugly wrinkles.

A bet on Bausch is a bet on Joseph Papa. At today’s levels, I like that bet.

Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. The Motley Fool owns shares of Bausch Health Companies.

More on Investing

ETF stands for Exchange Traded Fund
Dividend Stocks

How to Invest Your $7,000 TFSA Contribution in 2024

Here's how I would prioritize a $7,000 TFSA contribution for growth and income.

Read more »

a man relaxes with his feet on a pile of books
Dividend Stocks

CPP Pensioners: Watch for These Important Updates

The CPP is an excellent tool for retirees, but be sure to stay on top of important updates like these.

Read more »

Technology
Dividend Stocks

TFSA Investors: 3 Dividend Stocks I’d Buy and Hold Forever

These TSX dividend stocks are likely to help TFSA investors earn steady and growing passive income for decades.

Read more »

money goes up and down in balance
Investing

Unveiled: 2 Must-Watch Stocks for Your TFSA Before 2025

Value-conscious TFSA investors should consider Bank of Nova Scotia (TSX:BNS) and another great dividend pick.

Read more »

four people hold happy emoji masks
Dividend Stocks

Love Dividend Growth? Check Out These 2 Income-Boosting Stocks

National Bank of Canada (TSX:NA) and another Canadian dividend-growth stock are looking like a bargain going into December 2024.

Read more »

An investor uses a tablet
Dividend Stocks

A Dividend Giant I’d Buy Over Enbridge Stock Right Now

Enbridge stock may seem like the best of the best in terms of dividends, but honestly this one is far…

Read more »

how to save money
Dividend Stocks

Got $1,000? The 3 Best Canadian Stocks to Buy Right Now

If you're looking for some cash flow from your $1,000 investment, these are the ideal investments to make.

Read more »

Data center servers IT workers
Tech Stocks

Better Buy: Shopify Stock or Constellation Software?

Let's dive into whether Shopify (TSX:SHOP) or Constellation Software (TSX:CSU) are the better options for growth investors in this current…

Read more »